Seeking Alpha
Profile| Send Message|
( followers)  

With ASCO 2011 rapidly approaching, investors are scrambling to find the next big run up candidate to the June 3-7th oncology showcase. Less than a month away, the list of presenters can be a formidable task to review and research to find likely candidates. The 100% increase in the share price of Oxigene (NASDAQ: OXGN) from Monday’s low of 1.74 to Friday’s close of 3.56 is a prime example of the gains investors can experience with the right picks. The following is a list of companies selected from ASCO’s website that are possible candidates. The list has been dramatically narrowed down to only include publicly traded biotech, healthcare service and pharmaceutical companies on NASDAQ, AMEX and OTCBB. The list was further reduced to contain only companies with market capitalization values less than $1 billion, which are ones most likely to experience volatility and speculative run-up leading to June 3rd. While certainly not an exhaustive look at the securities, this should be a solid starting point to begin due diligence with market cap, price per share, institutional ownership, 52-week ranges of the securities, RSI, links to the companies’ websites and pipelines and other links to pertinent sites to facilitate solid and much quicker investor research.

Investors will be trading these securities with a host of long and short positions with many exiting their positions before the actual presentations are made to reduce risk. However, there will be some risk-averse few that will be holding through the data presentations to experience the price spike or drop (depending on their positions) that they perceive will happen. The author recommends only doing the latter if the investor is thoroughly educated in the risks and has done the appropriate research via previous interim data on the trials and earlier trials on the late stage drugs/devices along with other due diligence. For the “run up” method of investing, appropriate stop limits should be utilized to reduce risk of losing gains already experienced and to help guard against the price dip often occurring during the latter days before ASCO presentations when many investors choose to close out their positions.
Accuray Inc. – (NASDAQ: ARAY)
Market Cap - $551 Million
PPS – 7.98
52-week range: 5.77 – 11.16
RSI (20 day) – 26.7
Institution Ownership – 63%
Agenus, Inc. – (NASDAQ: AGEN)
Market Cap - $102.5 Million
PPS – 0.91
52-week range: 0.73 – 1.48
RSI (20 day) – 43.9
Institution Ownership – 20%
Allos Therapeutics, Inc. – (NASDAQ:ALTH)
Market Cap - $295 Million
PPS – 2.80
52-week range: 2.50 – 8.10
RSI (20 day) – 28.96
Institution Ownership – 98%
Alnylam Inc. – (NASDAQ:ALNY)
Market Cap – $420 Million
PPS – 9.92
52-week range: 8.79 – 17.07
RSI (20 day) – 49.14
Institution Ownership – 49%
ASCO Exhibitor Information - not listed on ASCO list of 2011, however Alnylam mentioned it in a March 31st press release http://www.advfn.com/news_Alnylam-Completes-Enrollment-in-ALN-VSP-Phase-I-Clinical-Trial_47101607.html
BioClinica - (NASDAQ:BIOC)
Market Cap - $82.6 Million
PPS – 5.26
52-week range: 3.13 – 5.60
RSI (20 day) – 57.25
Institution Ownership – 38%
BioScrip, Inc. – (NASDAQ:BIOS)
Market Cap - $362 Million
PPS – 6.51
52-week range: 4.00 – 8.29
RSI (20 day) – 70.95
Institution Ownership – 77%
Cell Therapeutics, Inc. – (NASDAQ:CTIC)
Market Cap - $347 Million
PPS – 0.317
52-week range: 0.21 – 0.55
RSI (20 day) – 33.75
Institution Ownership – 6%
Delcath Systems, Inc. – (NASDAQ: DCTH)
Market Cap - $278.5 Million
PPS – 6.41
52-week range: 5.35 – 16.33
RSI (20 day) – 35.63
Institution Ownership – 27%
Generex Biotechnology Corp. – (OTC: GNBT)
Market Cap - $64.91 Million
PPS – 0.22
52-week range: 0.20 – 0.56
RSI (20 day) – 43.33
Genomic Health, Inc. – (NASDAQ:GHDX)
Market Cap - $741.9 Million
PPS – 25.92
52-week range: 11.94 – 27.99
RSI (20 day) – 45.13
Institution Ownership – 81%
Genta, Inc. - (OTC:GNTA)
Market Cap - $2.30 Million
PPS – 0.0475
52-week range: 0.0225 – 0.31
RSI (20 day) – 50.86
Institution Ownership – 2%
GTx, Inc. – (NASDAQ:GTXI)
Market Cap - $273.6 Million
PPS – 5.20
52-week range: 1.90 – 5.38
RSI (20 day) – 90.63
Institution Ownership – 19%
Immunomedics, Inc. – (NASDAQ:IMMU)
Market Cap - $290.1 Million
PPS – 3.91
52-week range: 2.81 – 4.32
RSI (20 day) – 50.33
Institution Ownership – 33%
Oxigene, Inc. – (NASDAQ:OXGN)
Market Cap – $26.6 Million
PPS – 3.561
52-week range: 1.52 – 21.20
RSI (20 day) – 79.95
Institution Ownership – 1.90% (conflicting numbers listed)
ASCO Exhibitor Information – not listed on ASCO list of 2011, but data to be presented announced in press release http://investor.oxigene.com/releasedetail.cfm?releaseid=558908
Peregrine Pharmaceuticals, Inc. – (NASDAQ:PPHM)
Market Cap - $152.1 Million
PPS – 2.31
52-week range: 1.25 – 4.00
RSI (20 day) – 36.7
Institution Ownership – 13%
Response Genetics – (NASDAQ:RGDX)
Market Cap - $38.6 Million
PPS – 2.16
52-week range: 1.93 – 3.38
RSI (20 day) – 53.62
Institution Ownership – 50%
Spectrum Pharmaceuticals, Inc.- (NASDAQ:SPPI)
Market Cap - $417.1 Million
PPS – 8.27
52-week range: 3.67 – 10.63
RSI (20 day) – 42.25
Institution Ownership – 30%
Synta Pharmaceuticals Corp. – (NASDAQ:SNTA)
Market Cap - $240.8 Million
PPS – 5.86
52-week range: 2.55 – 6.93
RSI (20 day) – 57.45
Institution Ownership – 15%
Transgenomic, Inc. - (OTC:TBIO)
Market Cap - $41.9 Million
PPS – 0.85
52-week range: 0.30 – 0.96
RSI (20 day) – 43.75
Institution Ownership – 44%
WaferGen Biosystems - (OTC:WGBS)
Market Cap - $28.5 Million
PPS – 0.72
52-week range: 0.65 – 2.39
RSI (20 day) – 40.92
Institution Ownership – 7%
ASCO Exhibitor Information - listed on http://chicago2011.asco.org/LinkClick.aspx?fileticket=LHwyfOOSZjk%3D&tabid=1190 but no exhibitor information on website
YM Biosciences – (AMEX:YMI)
Market Cap - $342 Million
PPS – 3.10
52-week range: 1.06 – 3.47
RSI (20 day) – 65.58
Institution Ownership – 17%
ASCO Exhibitor Information - not listed on ASCO list of 2011, but listed on YM Biosciences calendar of events http://www.ymbiosciences.com/investors/events.php
Source: A Simplified ASCO 2011 List for Biotech Investor Research